Indaptus Therapeutics (INDP) Stock Overview

A clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. More details

INDP fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($4M)

Has less than 1 year of cash runway

Earnings have declined by 22.5% per year over past 5 years

+ 2 more risks

INDP Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Indaptus Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Indaptus Therapeutics
Historical stock prices
Current Share Price	US$1.75
52 Week High	US$19.91
52 Week Low	US$1.51
Beta	1.39
1 Month Change	-24.89%
3 Month Change	-0.57%
1 Year Change	-85.12%
3 Year Change	-97.01%
5 Year Change	n/a
Change since IPO	-99.30%

Recent updates

Analysis Article • Mar 27

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analysis Article • Aug 15

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Aug 08

Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45

Indaptus Therapeutics press release (NASDAQ:INDP): Q2 GAAP EPS of -$0.46 beats by $0.45. As of June 30, 2022, the Company had cash, cash equivalents and short-term investments of approximately $33.0 million. As of December 31, 2021, the Company had cash and cash equivalents of approximately $39.1 million.

Seeking Alpha • Sep 29

Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications

Indaptus Therapeutics is advancing the Decoy bacteria triggered immune response technology for cancer and viral indications. The company was formed from the reverse merger of Intec Pharma and Decoy Biosystems. Shares of the company commenced trading on Nasdaq on August 4, 2021.

Shareholder Returns

	INDP	US Biotechs	US Market
7D	-13.8%	1.0%	1.1%
1Y	-85.1%	40.3%	26.7%

Return vs Industry: INDP underperformed the US Biotechs industry which returned 44.4% over the past year.

Return vs Market: INDP underperformed the US Market which returned 25.4% over the past year.

Price Volatility

Is INDP's price volatile compared to industry and market?
INDP volatility
INDP Average Weekly Movement	16.0%
Biotechs Industry Average Movement	10.7%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: INDP's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: INDP's weekly volatility has decreased from 22% to 16% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
n/a	5	Junyi Dai	indaptusrx.com

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.

Indaptus Therapeutics, Inc. Fundamentals Summary

How do Indaptus Therapeutics's earnings and revenue compare to its market cap?
INDP fundamental statistics
Market cap	US$3.92m
Earnings (TTM)	-US$20.85m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Is INDP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INDP income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$20.85m
Earnings	-US$20.85m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-9.30
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did INDP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/14 17:49
End of Day Share Price	2026/05/14 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Indaptus Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jason McCarthy	Maxim Group

Indaptus Therapeutics (INDP) Stock Overview

Risk Analysis

Indaptus Therapeutics, Inc. Competitors

Galmed Pharmaceuticals

Alzamend Neuro

Shuttle Pharmaceuticals Holdings

Revelation Biosciences

Price History & Performance

Recent News & Updates

New major risk - Revenue and earnings growth

New major risk - Financial position

High number of new directors

Indaptus Therapeutics, Inc. Appoints David Natan as A Class II Director

Less than half of directors are independent

Indaptus Therapeutics, Inc. Announces Resignations of Board Members Michael Newman, Mark Gilbert, and Anthony Maddaluna

Recent updates

New major risk - Revenue and earnings growth

New major risk - Financial position

High number of new directors

Indaptus Therapeutics, Inc. Appoints David Natan as A Class II Director

Less than half of directors are independent

Indaptus Therapeutics, Inc. Announces Resignations of Board Members Michael Newman, Mark Gilbert, and Anthony Maddaluna

Forecast to breakeven in 2028

Indaptus Therapeutics, Inc. announced that it expects to receive $6 million in funding

New major risk - Financial position

Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.375 million.

New major risk - Financial position

Indaptus Therapeutics, Inc. announced that it has received $3.4 million in funding

Indaptus Therapeutics, Inc. announced that it has received $2.3 million in funding

Indaptus Therapeutics Doses First Patient in Phase 1B/2 Combination Study of Decoy20 with Pd-1 Checkpoint Inhibitor Tislelizumab

New minor risk - Share price stability

New major risk - Financial position

Indaptus Therapeutics, Inc., Annual General Meeting, Jun 10, 2025

New major risk - Market cap size

Indaptus Therapeutics, Inc. Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with Pd-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening Its Intellectual Property for Infectious Disease and Cancer Treatments

Indaptus Therapeutics, Inc. announced that it expects to receive $20 million in funding from Yorkville Advisors Global LP

Indaptus Therapeutics, Inc. Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Indaptus Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirements

Indaptus Therapeutics, Inc. announced that it has received $2.246493 million in funding

New major risk - Shareholder dilution

Indaptus Therapeutics, Inc. announced that it expects to receive $2.246493 million in funding

New major risk - Market cap size

Insufficient new directors

Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.134995 million.

New major risk - Financial position

Indaptus Therapeutics, Inc. Presents Clinical Data on Decoy20 at SITC 2024 Annual Meeting

Indaptus Therapeutics, Inc. Provides Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

New minor risk - Shareholder dilution

Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.000003 million.

Indaptus Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.3 million.

Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20

Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?

New major risk - Financial position

New minor risk - Share price stability

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial

Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20

Indaptus Therapeutics, Inc. Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?

Indaptus Therapeutics, Inc. Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Indaptus Therapeutics, Inc. Appoints Roger Waltzman as Its Chief Medical Officer, Effective August 7, 2023

Price target increased by 15% to US$15.00

Indaptus Therapeutics, Inc. Names Robert Martell, M.D., Ph.D. to Its Board of Directors

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Price target decreased to US$11.00

High number of new and inexperienced directors

Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45

Indaptus Therapeutics, Inc., Annual General Meeting, Sep 29, 2022

CEO & Director recently bought US$52k worth of stock

Indaptus Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

High number of new and inexperienced directors

High number of new and inexperienced directors

CEO & Director recently bought US$65k worth of stock

Insider recently bought US$691k worth of stock

Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications

CEO & Director recently bought US$84k worth of stock

Shareholder Returns